HUTCHMED (China) (HMDCF) Non-Current Debt (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Non-Current Debt came in at $72.1 million in Q2 2026, up 6.28% year-over-year from $67.8 million in Q2 2025, and up 5.74% quarter-over-quarter from $68.2 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Non-Current Debt (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Non-Current Debt for 12 consecutive years, with $72.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non-Current Debt rose 6.28% year-over-year to $72.1 million in Q2 2026; TTM through Jun 2026 was $72.1 million, a 6.28% increase from a year earlier, with the FY2025 full-year figure at $68.2 million, changed N/A from the prior year.
- Non-Current Debt was $72.1 million for Q2 2026 at HUTCHMED (China), up from $68.2 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $72.1 million in Q2 2026 and troughed at $418000.0 in Q2 2022.
- A 5-year average of $46.1 million and a median of $55.6 million in 2024 frame the typical range for Non-Current Debt.
- Across the five-year window, Non-Current Debt surged 9504.55% in 2023 and advanced 6.28% in 2026, its largest moves.
- Over 5 years, Non-Current Debt stood at $18.1 million in 2022, then soared by 121.76% to $40.1 million in 2023, then surged by 38.57% to $55.6 million in 2024, then rose by 22.57% to $68.2 million in 2025, then increased by 5.74% to $72.1 million in 2026.
- The last three Non-Current Debt figures came in at $72.1 million (Q2 2026), $68.2 million (Q4 2025), and $67.8 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 72.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 72.10 Mn |
| Dec 31, 2025 | 68.19 Mn |
| Jun 30, 2025 | 67.84 Mn |
| Jun 30, 2024 | 55.63 Mn |
| Jun 30, 2023 | 40.15 Mn |
| Dec 31, 2022 | 18.10 Mn |
| Jun 30, 2022 | 418,000.00 |
| Mar 31, 2021 | 26.87 Mn |
| Dec 31, 2020 | 26.86 Mn |
| Jun 30, 2020 | 26.84 Mn |
| Dec 31, 2019 | 26.82 Mn |
| Mar 31, 2019 | 26.76 Mn |
| Dec 31, 2018 | 26.74 Mn |
| Jun 30, 2018 | 26.69 Mn |
| Jun 30, 2017 | 19.99 Mn |
| Dec 31, 2016 | 26.83 Mn |
| Jun 30, 2016 | 26.80 Mn |
| Dec 31, 2015 | 26.77 Mn |